Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy

Marcella Caggiula, Anna Paola Batocchi, Giovanni Frisullo, Francesco Angelucci, Agata Katia Patanella, Cristina Sancricca, Viviana Nociti, Pietro Attilio Tonali, Massimiliano Mirabella

Research output: Contribution to journalArticle

Abstract

Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.

Original languageEnglish
Pages (from-to)77-82
Number of pages6
JournalClinical Immunology
Volume118
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Chronic Progressive Multiple Sclerosis
Interferon-beta
Brain-Derived Neurotrophic Factor
Nerve Growth Factors
Nerve Growth Factor
Multiple Sclerosis
Neurotrophin 3
Glial Cell Line-Derived Neurotrophic Factor
Astrocytes
Disease Progression
Blood Cells
Therapeutics
Endothelial Cells
Brain

Keywords

  • Brain-derived neurotrophic factor
  • Disease-modifying therapy
  • Glial cell line-derived neurotrophic factor
  • Interferon beta
  • Multiple sclerosis
  • Nerve growth factor
  • Neuroprotection
  • Neurotrophin 3
  • Neurotrophin 4/5
  • Neurotrophins

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Caggiula, M., Batocchi, A. P., Frisullo, G., Angelucci, F., Patanella, A. K., Sancricca, C., ... Mirabella, M. (2006). Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clinical Immunology, 118(1), 77-82. https://doi.org/10.1016/j.clim.2005.09.005

Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. / Caggiula, Marcella; Batocchi, Anna Paola; Frisullo, Giovanni; Angelucci, Francesco; Patanella, Agata Katia; Sancricca, Cristina; Nociti, Viviana; Tonali, Pietro Attilio; Mirabella, Massimiliano.

In: Clinical Immunology, Vol. 118, No. 1, 01.2006, p. 77-82.

Research output: Contribution to journalArticle

Caggiula, M, Batocchi, AP, Frisullo, G, Angelucci, F, Patanella, AK, Sancricca, C, Nociti, V, Tonali, PA & Mirabella, M 2006, 'Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy', Clinical Immunology, vol. 118, no. 1, pp. 77-82. https://doi.org/10.1016/j.clim.2005.09.005
Caggiula, Marcella ; Batocchi, Anna Paola ; Frisullo, Giovanni ; Angelucci, Francesco ; Patanella, Agata Katia ; Sancricca, Cristina ; Nociti, Viviana ; Tonali, Pietro Attilio ; Mirabella, Massimiliano. / Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. In: Clinical Immunology. 2006 ; Vol. 118, No. 1. pp. 77-82.
@article{ee890b22cfa54bb8ab3aaa818badb5f8,
title = "Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy",
abstract = "Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.",
keywords = "Brain-derived neurotrophic factor, Disease-modifying therapy, Glial cell line-derived neurotrophic factor, Interferon beta, Multiple sclerosis, Nerve growth factor, Neuroprotection, Neurotrophin 3, Neurotrophin 4/5, Neurotrophins",
author = "Marcella Caggiula and Batocchi, {Anna Paola} and Giovanni Frisullo and Francesco Angelucci and Patanella, {Agata Katia} and Cristina Sancricca and Viviana Nociti and Tonali, {Pietro Attilio} and Massimiliano Mirabella",
year = "2006",
month = "1",
doi = "10.1016/j.clim.2005.09.005",
language = "English",
volume = "118",
pages = "77--82",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy

AU - Caggiula, Marcella

AU - Batocchi, Anna Paola

AU - Frisullo, Giovanni

AU - Angelucci, Francesco

AU - Patanella, Agata Katia

AU - Sancricca, Cristina

AU - Nociti, Viviana

AU - Tonali, Pietro Attilio

AU - Mirabella, Massimiliano

PY - 2006/1

Y1 - 2006/1

N2 - Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.

AB - Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.

KW - Brain-derived neurotrophic factor

KW - Disease-modifying therapy

KW - Glial cell line-derived neurotrophic factor

KW - Interferon beta

KW - Multiple sclerosis

KW - Nerve growth factor

KW - Neuroprotection

KW - Neurotrophin 3

KW - Neurotrophin 4/5

KW - Neurotrophins

UR - http://www.scopus.com/inward/record.url?scp=29444451569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444451569&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2005.09.005

DO - 10.1016/j.clim.2005.09.005

M3 - Article

C2 - 16275091

AN - SCOPUS:29444451569

VL - 118

SP - 77

EP - 82

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -